Skip to main content

Table 2 FLT3 inhibitors in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
Sorafenib   Flt3-ITD+ Relapsed and refractory AML 200 mg-800 mg qd retrospective 26 CHR: 88% [25]
Sorafenib as part of induction therapy and salvage FLT3+AML, untreated Relapsed   retrospective 128 CR/CRp: 7% [26]
Sorafenib   FLT3+AML
Relapsed and refractory
800 mg q.d retrospective 8 CR: 25% [27]
Sorafenib Idarubicin, cytarabine FLT3+AML untreated 400 mg po bid ×7 d Phase II 18 CR/CRp: 94% [28]
  1. Abbreviations: CR: complete remission; CRp: CR without platelet recovery; CHR: complete hematological response